ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
78.50
-1.10 (-1.38%)
At close: Apr 28, 2026, 4:00 PM EDT
78.50
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:01 PM EDT
Company Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers.
ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2001 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 970 |
| CEO | Nikhil Lalwani |
Contact Details
Address: 210 Main Street West Baudette, Minnesota 56623 United States | |
| Phone | 218 634 3500 |
| Website | anipharmaceuticals.com |
Stock Details
| Ticker Symbol | ANIP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001023024 |
| CUSIP Number | 00182C103 |
| ISIN Number | US00182C1036 |
| Employer ID | 58-2301143 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nikhil Lalwani | President, Chief Executive Officer and Director |
| Stephen P. Carey | Senior Vice President of Finance and Chief Financial Officer |
| Meredith W. Cook J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Christopher K. Mutz | Senior Vice President and Head of Rare Disease |
| Ori Gutwerg | Senior Vice President of Generics |
| Muthusamy Shanmugam MS R.Ph. | Head of Research & Development, Chief Operating Officer of New Jersey Operations and Director |
| Elizabeth Powell J.D. | Chief Compliance Officer and Head of Legal of Rare Disease |
| Chad Gassert | Senior Vice President of Corporate Development and Strategy |
| Krista L. Davis | Senior Vice President and Chief Human Resources Officer |
| Dr. Mary Pao M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2026 | ARS | Filing |
| Apr 9, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 5, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 27, 2026 | 10-K | Annual Report |
| Feb 27, 2026 | 8-K | Current Report |